ImmuMed A Therapeutic Antibody Company Corporate Overview August 2013 Private and Confidential ImmuMed Inc.© 2013 Confidential ImmuMed Profile Private therapeutic antibody company Mission: To utilize our proprietary therapeutic antibody platform and build a leading organ transplantation business and transform the field by expanding recipient eligibility and enabling universal organ donor transplants Established Lead product: Anti-Lymphocyte Globulin (ALG) – Historical use in 52,000 in organ transplant recipients at over 281 transplant centers across the U.S., Canada and parts of Europe – Primary indication: Induction Therapy (Prevention of Acute Rejection) – Published scientific record of efficacy and safety, support from KOLs in transplant Antibody Platform and Pipeline Portfolio targeting antibody markets > $3B ImmuMed Inc.© 2013 Confidential 3 Investment Thesis – ROI vs R&D process mitigates risk Initial transplant antibody market size estimated at $470M W/W - 85% of revenue earned from Induction Therapy ** Opportunity to revive proven product used in over 52,000 patients – Task: update mfg. and reproduce historical tox data to satisfy FDA IND requirement $30M investment to market-rollout first product – $10M to kick-off Ph III and potential IPO Projected $250M+ in revenue within 5 years Competitor with $79M in revenue sold for $600M in 2003 (8X multiple) Additional revenue from pipeline development funded by product sales ** Induction Therapy is a drug protocol employing the administration of therapeutic antibodies to prevent rejection immediately following organ transplantation ImmuMed Inc.© 2013 Confidential 4 Market Value Proposition Growing organ transplantation industry – Increasing demand for organ transplants (W/W) – Global Shortage of Donor Organs (growing waiting lists) – Increasing Use of High-Risk Donor Organs (must use polyclonal antibody) Fragmented market without a clear leader – Multiple products are sold into the field on a fragmented basis Clear unmet transplantation medical need – No product enables universal organ donation – No polyclonal antibody currently licensed for induction therapy – No product addresses sensitized recipients – Key anti-rejection products are marginally effective or sold “off-label” ImmuMed well positioned for: – Market expansion by enabling universal organ transplants – Capture the sales of current products now being used off-label – Consolidation of existing products and businesses – Market leadership to Establish Induction Therapy as Standard of Care ImmuMed Inc.© 2013 Confidential 5 Competitive Landscape for Induction Therapy Antibody-based Immunosuppressive Drugs Monoclonal Antibodies (Low Risk Recipients) 5% US Revenue Share – Single antigenic site with high specificity – Two (Simulect,® Zenapax®) approved to prevent rejection – One (OKT3) approved to treat acute rejection Polyclonal Antibodies (High Risk Recipients) 95% US Revenue Share - Multiple antigenic sites – cytotoxic activity – None approved for prevention of rejection – Two approved (Thymoglobulin® , Atgam®) to treat acute rejection – Treatment of Acute Rejection by antibodies – occurs in 4% of transplants – Antibody revenues (Induction Therapy) now driven by Off-Label Use – See IALG advantages vs. Thymoglobulin – More efficient production at higher margins – Absence of 10% microaggregates less safety concerns ImmuMed Inc.© 2013 Confidential 6 2012 Global Antibody Sales Approved Polyclonal & Monoclonal Antibodies Product Name Thymoglobulin® (Rabbit) Type of Product Polyclonal Manufacturer Genzyme Indication $$ Sales ($Millions) % Change vs. PY Rx AR $320 12.0 % Simulect® (Murine) Monoclonal Novartis Induction $110 4.5 % rATG * (Rabbit) Polyclonal Fresenius Rx AR $ 40 8.0 % * Not sold in U.S. Source: Evaluate Pharma 2013 ImmuMed Inc.© 2013 Confidential 7 Technology Background • Therapeutic antibody technology acquired from U. Minnesota 1996 • $66M R&D investment already done • Lead product: ImmuMed Anti-Lymphocyte Globulin (“IALG”) • Primary indication: prevent rejection after solid organ transplantation • 52,000 patient administrations (Compassionate Use) at least 281 transplant centers across the U.S., Canada and parts of Europe Lack of sufficient data reporting on compassionate use caused FDA clinical hold University refused commercial drug production FDA issue with original inventor resolved • • • • Multiple pipeline products from common plasma inventory • • • • Precondition donor tissue for bone marrow and stem cell transplants Aplastic anemia Autoimmune diseases Lymphomas (FAB2 form) • Qualified strategic partners identified • • • • CMO: Cangene and/or Therapure BioPharmaceutical CSO: Bio-Reliance and Apptec CSO: Lake Immunogenics CRO: Cato Research; Kendle; CTI ImmuMed Inc.© 2013 Confidential 8 Pipeline Common Manufacturing Platform PRODUCT PIPELINE Program Indication R&D PC ** Phase I Phase II Phase III Biological Antibodies ALG Solid Organ Transplantation IATG-BMT Bone Marrow Transplantation H. anti HIV Adjuvant Therapy in HIV and AIDS Recombinant Antibodies Fab2 Infectious Diseases ISI Mab Cancer Immunotherapy Additional Opportunities ** Of products in its portfolio, ImmuMed has prioritized the sequence in which to develop acquired compounds based on the current stage of clinical development listed below. ImmuMed Inc.© 2013 Confidential 9 Pipeline Target Markets • Lead product: ImmuMed Anti-Lymphocyte Globulin (“IALG”) • $470MM potential market oppty. based on existing drugs • Target markets for follow on pipeline products (derivatives of common plasma inventory = truncated development pathway) • Graft versus Host disease in Bone Marrow Transplant ($80MM) • Aplastic Anemia ($175MM) • Reduced viral loads in CMV and HIV infected patients ($750MM) • B-cell lymphoma ($30MM) • B-Cell Mediated Auto-Immune Diseases ($125MM) • IVIG ($1.4B) ImmuMed Inc.© 2013 Confidential 10 How Does IALG Work? - Adjuvant Immunosuppressive Drug Adjuvant = administration as add-on to background immunosuppressive regimens to improve outcomes - Mechanism of Action Cytotoxic to lymphocytes (including those causing acute organ rejection ) Decreases: Recognition of Foreign Antigen Incidence of Acute Rejection Incidenceof Post-op dialysis events - Degraded by Liver • Anti-IALG antibodies occasionally measured ImmuMed Inc.© 2013 Confidential 11 Clinical Development Summary Published Scientific Studies Human Studies Sample Size Major Findings Phase I (1) Pharmacokinetics (N = 104) Depletion Circulating lymphocytes Dose response in humans Phase II (2) a) Skin grafts (N = 102) b) Renal grafts (N = 47) Phase III (3) Study drug v. Placebo Renal grafts (N = 160) Increased graft survival was dose related Therapeutic Benefit improved renal graft survival at 1 & 3 years ** No Safety Issues ** 1) Buchman TE., et al; Transplantation. 55(5):1190-3, 1993 May. 2) Simmons RL. Moberg AW., et al: Surgery. 68(1):62-8, 1970 Jul. 3) Condie RM, et al, Transplantation proceeding 1985; XVII(1): 1304-1311. ImmuMed Inc.© 2013 Confidential 12 Phase III Trial Efficacy: Enhanced Graft Survival ALG versus Placebo (Phase III study) Multicenter Efficacy Study for Induction Therapy Post-Transplant Event ALG (n=81) Albumin (n=79) P-Value Efficacy Graft Survival: 1 year 48/81 (59%) 37/79 (47%) p = 0.02 Graft Survival: 3 years 45/81 (56%) 18/79 (23%) p<0.015 First rejection episode (median) 28 days 11 days 24.7% 13.6% 11.1% 7.4% 49.4% 15.2% 6.3% 13.9% 2.5% 55.7% p<0.0001 Safety Fever Chills Hematuria Nausea Infections ImmuMed Inc.© 2013 Confidential NS NS NS NS NS 13 Comparative Performance Equine vs. Rabbit IALG vs. Rabbit Antithymocyte Globulin [Comparative Efficacy for Induction Immunosuppression] Univ Hospital of Cincinnati Cincinnati, OH + 4 other hospitals % Patient Survival 6 months 12 months rATG (n=50) ALG (n=48) p value 98+1.98 96+2.77 95.8+2.9 95.8+2.9 NS NS % Graft Survival 6 months 12 months 83.9+5.2 81.7+5.5 87.5+4.8 84.6+5.4 NS NS % Patients with Rejection 12 months 60 (30) 50 (24) NS Serum Creatinine (mean) 6 months 12 months 1.90+1.6 1.91+.22 1.87+.13 1.72+.07 NS NS ImmuMed Inc.© 2013 Confidential 14 IALG: Favorable Sample Size and AE/SAE Rates Renal Transplant Patients ALG(1) Atgam(2) OKT3(2) Thymoglobulin(2) Simulect(2) Safety Database 8,059 1,587 63 82 193 Incidence of Death 0.5% 28.0% 4.7% 7.3% 4.6% (1) ALG data derived from all of the Case Report Forms submitted by transplant centers utilizing ALG in response to a letter request from the University of Minnesota pursuant to the clinical hold imposed by FDA. They represent data from all of the renal transplant patients from December 28, 1988 to August 12, 1992. (2) Data from FDA’s summary basis of approval. ImmuMed Inc.© 2013 Confidential 15 Proven Polyclonal Market (Thymoglobulin) Sales and Market valuation of Thymoglobulin have soared due to: Off-label use Absence of competitors 1993 History 1993 1998 Sangstat (California) Licensed Lymphoglobuline, N.A. Renames: Thymoglobulin Pasteur Merioux (France) Product: Lymphoglobuline in EU 18.7% 2003 $91M ImmuMed Inc.© 2013 17.8% 11.5% 21.9% 2012 $320 M Q4 – Sangstat Acquires Thymoglobulin From Pasteur Merioux: Q1 – Sangstat Secondary Offering @ $30 share, 2.6 M shares H&Q lead, others Q3 – Sangstat IPO @ $7.50 per share Piper lead, H&Q, others 18.5% 1980 2003 $31M 1997 Q3 – Genzyme Acquires Sangstat $600M 2006 $156M 17.2% 7.1% 2009 $232M 2010 $250M 2008 $198M 2007 $168M Sales 2005 $128M 2004 $108M ** Sales to 2010 derived from 10Q filings; since Sanofi purchase current sales (2012) independent estimate Confidential 16 IALG Competitive Advantages IALG Thymoglobulin ImmuMed Sanofi Production 1 Horse = 140 liters Efficiency 2,800 Rabbits = 140 liters Large Plasma Inventory Mfg. Volumes Low Inventory Potential Liquid Solution Always Physical State Powder-Freeze Dried Market Factors High Gross Margins Fraction of MALG Safety & Efficacy Antigen Type T-Cell Only 99% Purity 90% <1% Micro-aggregates 10% B-Cell T-Cell ImmuMed Inc.© 2013 Confidential 17 Strong Intellectual Property IALG ADVANTAGE Proprietary Patentable Essential to Developing Biologic Activity Essential to Not Destroying Biologic Activity Immunogens T-cells B-cell (available only for IALG) Newly Formulated Plasma Purification Process Method of Immunization Method of Lot Formulation New Patent Proprietary + Data + New Patent Claims = Unique Phase 3 Product ImmuMed Inc.© 2013 Confidential 18 Multiple Registration Plans Available for IALG Pivotal Trial Options Available US Trial Potentials Label NIT to Standard of Care Induction Label NIT to Simulect or Zenapax Induction Label Superiority to Simulect or Zenapax Induction Label NIT to Atgam or Thymoglobulin Rejection Treatment Differential Dosing (high/low IALG dose) Induction Label Non-US Trial Potentials Study drug vs. Placebo; Induction Protocol Superiority to Simulect or Zenapax NIT to Simulect or Zenapax; Induction Protocol Current Status: No Approved Polyclonal Standard of Care for Induction ImmuMed Inc.© 2013 Confidential 19 FDA Pathway / Regulatory Milestones Marketing approval for a large molecule biologic based on standardized method of manufacturing correlated with safety and therapeutic benefit data discovered pursuant to a pivotal clinical trial. Based on Pre-IND Meetings, ImmuMed required to: • • • • • • Finalize manufacturing method (finished by vendor) Manufacture commercial size lots (sufficient for 2,400 patients) Repeat toxicity study (required for new manufacturing process) Submit new IND for IALG pivotal clinical trial (drafted) Complete nested dosing and pivotal trial File BLA using new acquired data ImmuMed Inc.© 2013 Confidential 20 IALG Revenue Model IALG Pro Forma vs. Expected Global Market (5% Projected Growth) 7 00 .0 6 47 .8 Funding 5 87 .6 Millions USD 6 00 .0 5 33 .0 4 70 .0 5 00 .0 4 00 .0 3 00 .0 2 46 .8 2 00 .0 9 7.2 1 00 .0 Pro Forma 1 9.3 0 .0 0 .0 Global 1 99 2 8 3.9 2 00 3 2 01 2 2 7.3 2 01 4 2 01 6 2 01 8 Ye ar ImmuMed Inc.© 2013 Confidential 21 Business Objectives Complete Market Approvals for IALG - Induction Therapy Indication - Ph IV study for chronic rejection (3 and 5 year end-points) - Expand life-cycle for desensitization therapy Early Market Exposure and Revenues - Secondary Retransplant Market in US – (≈ 2,000 / year) - “Named-Patient” sales – EU and rest of world (ROW) – Emergency drug release authorization (Canada) Product Launches First on-label product in induction therapy(≈ 36 months) Capture “Off-Label sales; gain market share from monoclonals First product for desensitization (if studied) Consolidate products/market as single industry leader ImmuMed Inc.© 2013 Confidential 22 Business Model Vision: Begin As Near Virtual Company during pre-revenue period Minimal Infrastructure, Rely On Outsourcing Avoid Amassing Overhead In Search of Products Focus On Achieving Early Cash Flow Projected 12 to 15 Months Commercialize Established Polyclonal Antibodies First No Early R & D Expense Build Infrastructure, R & D With Cash Flow Expand Acquired Portfolio; In-License or Acquire New Technologies Execution: Build the ImmuMed Company Restart IALG Production ImmuMed Inc.© 2013 O U T S O U R C E Material Prod Testing FDA Phase III IND IALG #1 Sales Trials Confidential Strategic Alliances for Distribution R&D Outsourcing Co-Develop IPO Acquired Merge 23 Mitigation of Investment Risk Reduced Regulatory & Development Risk – – – – – – – Multiple, well-defined FDA pathways (5 previous antibody products) No R & D required absence of surprises, efficacy understood 52,000 patient history to supplement new safety data Efficacy and superiority established Data points (safety, dose, efficacy) to be replicated, not new Manufacturing method establish/approved for another product type Proven Mfg. partners with experience in existing products Attractive Commercial Opportunities – – – – – – – Growing transplant market Product history demonstrates high medical approval Acceptance of safety and efficacy profile Multiple products derived from the same manufacturing platform High manufacturing COG margins Transplant market is mature, yet highly focused Only few dozen leading US transplant centers potentiates “80:20” market scenario. ImmuMed Inc.© 2013 Confidential 24 Executive Mgt. Martin Driscoll, Chairman of the Board of Directors - Presently CEO and Director of Asmacure Ltee, a venture-backed clinical-stage biopharmaceutical company. Previous CEO of Javelin Pharmaceuticals (acquired by Hospira, Inc. in 2010). Over 31 years’ experience in bio pharmaceutical industry with responsibility in commercial, business development, and general management at Schering-Plough, ViroPharma, and Reliant Pharmaceuticals. Allen Moberg, MD., Acting CEO/Director/CMO - Founder of ImmuMed, Inc.. Received his MD degree in 1964 and thereafter was educated in general and transplantation surgery at the University of Minnesota. Was responsible for development and patenting of medical devices for organ preservation and cofounder of IALG Program with other colleagues in the University of Minnesota’s Department of Surgery. Served as initial Program Director responsible for IALG’s production, Phase I and Phase II clinical testing, coa-uthored IND. Recent focus on organizing effort to return IALG to the marketplace, including raw material production and manufacturing and regulatory affairs. Thomas Burton, CFO/Director - Cofounder of ImmuMed. From 1960 to 1990, was President and CEO of Waters Instruments, Inc., a diversified publicly traded company [ZRBA-NASDAQ] manufacturing and marketing medical and electronic devices. Served by appointment by the Governor of Minnesota on the Public Utilities Commission. Recently consulting with principal investigators developing new products in the medical field. ImmuMed Inc. Confidential 25 Advisors Peter Levitch - Special expertise in clinical study design, implementation and compliance, good manufacturing practices and regulatory affairs. 25 years as consultant to more than 200 biotech, pharmaceutical and medical device companies, participating in at least 260 IND’s and FDA approval of many biotechnology derived products. Previous Manager of Clinical Research at Eaton Laboratories and Director of Clinical Research and Regulatory Affairs at Ortho Diagnostics, where, acting as Responsible Head to CBER (working to assure compliance for Ortho’s 60 licensed products) and as Official Correspondent to CMDRH. Thomas Stagnaro – Over 35 years’ experience in medical and biotechnology fields. Presently President, CEO and Founder of Americas Biotech Distributor, LLC., distributing US biotech products into Latin America. Previously President and CEO of Agile Therapeutics, Inc. Prior to Agile, pharmaceutical consultant to Rock Hill Ventures/Hillman Medical Ventures, and President and CEO of 3-Dimensional Pharmaceuticals, Inc. Former Senior Executive Vice President at NABI, responsible for sales and marketing, generating sales in excess of $250 million and served as in the research and development for human polyclonal antibody products and vaccines. At NABI, managed the “In-licensing” of a late-stage product, and successfully brought the product through CBER and launched in US. Prior to NABI, was President and CEO of Univax Biologics, Inc., (acquired by NABI in 1995 for $150 million). John St. Cyr, II, MD, Ph.D. - Director of Research. Surgical education at University of Minnesota, cardiovascular-thoracic training at University of Colorado Health Sciences, specializing in adult and pediatric Cardiovascular surgery, and transplantation. History in research, dedicated to myocardial preservation. ImmuMed Inc. Confidential 26 Investment Thesis – ROI vs R&D process mitigates risk Initial transplant antibody market size estimated at $470M W/W - 85% of revenue earned from Induction Therapy ** Opportunity to revive proven product used in over 52,000 patients – Task: update mfg. and reproduce historical tox data to satisfy FDA IND requirement $30M investment to market-rollout first product – $10M to kick-off Ph III and potential IPO Projected $250M+ in revenue within 5 years Competitor with $79M in revenue sold for $600M in 2003 (8X multiple) Additional revenue from pipeline development funded by product sales ** Induction Therapy is a drug protocol employing the administration of therapeutic antibodies to prevent rejection immediately following organ transplantation ImmuMed Inc.© 2013 Confidential 27